Lorem ipsum dolor amet elit dolor es (h1)

Maecenas fermentum, risus vitae malesuada euismod, urna arcu sodales leo, ac dapibus nisl purus porttitor quam

Nunc mattis in est ut
suscip quam (h2)

Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse porttitor, augue egestas aliquam porta, lacus turpis dignissim felis, at egestas lectus tellus a libero.

Duis mattis nisi risus. Integer pulvinar id odio gravida sagittis. Suspendisse maximus mi sit amet libero porttitor pellentesque ac et massa. Mauris elementum finibus accumsan. Nunc mattis in est ut suscipit. Vivamus ullamcorper augue arcu, non condimentum mauris finibus ac. Vestibulum sed facilisis nisi, sed pretium quam.

Nunc mattis in est ut
suscip quam (h2)

Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse porttitor, augue egestas aliquam porta, lacus turpis dignissim felis, at egestas lectus tellus a libero.

Duis mattis nisi risus. Integer pulvinar id odio gravida sagittis. Suspendisse maximus mi sit amet libero porttitor pellentesque ac et massa. Mauris elementum finibus accumsan. Nunc mattis in est ut suscipit. Vivamus ullamcorper augue arcu, non condimentum mauris finibus ac. Vestibulum sed facilisis nisi, sed pretium quam.

Contact form

LOREM IPSUM DOLOR ES

How do life sciences leaders
leverage our technology (h2)

Our solutions combine mobile and web technology, leveraging our proven Theraxium platform, with embedded evidence-based clinical algorithms to adjust treatment dosage, support adherence to treatment and manage symptoms related to the treatment and the disease. Our mission is to help deliver a better care by optimizing the real-world use of medication and, ultimately, improve real-world outcomes.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur magna augue, vehicula et imperdiet rhoncus, rutrum eu ipsum. Sed ultricies, enim sit amet maximus interdum, neque leo iaculis velit, sed finibus quam nulla id felis. Nulla eu rutrum dolor. Aenean est justo, egestas ac pellentesque facilisis, tincidunt sit amet diam.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur magna augue, vehicula et imperdiet rhoncus, rutrum eu ipsum. Sed ultricies, enim sit amet maximus interdum, neque leo iaculis velit, sed finibus quam nulla id felis. Nulla eu rutrum dolor. Aenean est justo!

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur magna augue, vehicula et imperdiet rhoncus, rutrum eu ipsum. Sed ultricies, enim sit amet maximus

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur magna augue, vehicula et imperdiet rhoncus, rutrum eu ipsum. Sed ultricies, enim sit amet maximus

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur magna augue, vehicula et imperdiet rhoncus, rutrum eu ipsum. Sed ultricies, enim sit amet maximus



To deliver differentiating treatment experiences to patient and care teams.



To deliver differentiating treatment experiences to patient and care teams.


To deliver differentiating treatment experiences to patient and care teams.



To deliver differentiating treatment experiences to patient and care teams.


To deliver differentiating treatment experiences to patient and care teams.

Nunc mattis in est ut
suscip quam (h3)

Nunc mattis in est ut suscip quam (h4)

  • On the commercial side, Voluntis is aiming to sign new cooperation agreements in 2021.
  • On the financial side, based on its current available information, the company confirms its annual commercial invoicing objective of between € 8 and 12 million, and still targets a positive free cash flow in the second half of the year.
    • On the financial side, based on its current available information, the company confirms
    • On the financial side, based on its current available information

Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse porttitor, augue egestas aliquam porta, lacus turpis dignissim felis, at egestas lectus tellus a libero.

Duis mattis nisi risus. Integer pulvinar id odio gravida sagittis. Suspendisse maximus mi sit amet libero porttitor pellentesque ac et massa. Mauris elementum finibus accumsan. Nunc mattis in est ut suscipit. Vivamus ullamcorper augue arcu, non condimentum mauris finibus ac. Vestibulum sed facilisis nisi, sed pretium quam.

Digitally-augmented therapies have the potential to address unmet needs for every actor of the health (pullquote).

How do life sciences leaders
leverage our technology (h2)

title h5

Our solutions combine mobile and web technology, leveraging our proven Theraxium platform, with embedded evidence-based clinical algorithms to adjust treatment dosage!

This is a quote year after the presentation of our new strategic roadmap, I am very proud of the progress we have made. We are on track on all key indicators, whether it is the conclusion of agreements, with new milestone partnerships with two leading pharmaceutical companies, the improvement of our results, thanks to the optimization of our cost structure, or our financial visibility with a growing cash flow. »

Pierre Leurent, CEO of Voluntis

Toggle content

Focus on patients that requires attention:

  • Extend their support to patients through a digital device they prescribe.
  • Intervene at the right time with the right data.
  • Leverage tools that promote evidence-based treatment management and supportive care strategies.

Life sciences companies

Toggle content

High patient engagement

At Voluntis, we share the vision that empowering patients to self-manage their treatment can improve

of patients contine with Insulia

AFTER 1 MONTH

of active patients interact with Insulia every day

AFTER 1 MONTH

At Voluntis, we share the vision that empowering patients:

LOREM IPSUM

of active patients acept Insulia’s recommanded dose

LOREM IPSUM

of active patients acept Insulia’s recommanded dose

Button & links

At Voluntis, we share the vision that empowering patients to self-manage their treatment can improve the overall treatment experience and efficiency. We are on a mission to deliver this vision through digitally-augmented therapies to put patients back in control of their disease. We believe that patients’ experience with their treatment can be improved by putting the right tool in their hands to:

Request a demo (large)

Request a demo (medium)

Request a demo (medium/secondary)

This is a link (large)

See all (medium)

Tables

We are on a mission to deliver this vision through digitally-augmented therapies to put patients back in control of their disease. We believe that patients’ experience with their treatment can be improved by putting the right tool in their hands to:

Table standard width

20192020
Sales invoicing2.710.2
Adjusted EBITDA(13.4)(3.4)
Operating income(13.4)(3.4)
Cash and cash equivalents net of financial debts(2.5)2.9

Table large width

2019202020212022
Sales invoicing2.710.22.710.2
Cash and cash equivalents net of financial debts2.710.22.710.2
Adjusted EBITDA2.710.22.710.2
Sales invoicing2.710.22.710.2

How do life sciences leaders
leverage our technology (h2)

Our solutions combine mobile and web technology, leveraging our proven Theraxium platform, with embedded evidence-based clinical algorithms to adjust treatment dosage, su

01
Design

We build medical algorithms based on cutting-edge science and design our solutions within the best practices in usability and human factors engineering

02
Development

We develop DTx that work in conjunction with therapies and/or sensors to help patients in the monitoring of their conditions. Our agile and expert team work hands in hands to develop solutions following the requirements for Software as Medical Device.

03
Validation

3

04
Regulatory approval

4

05
Deployment & Operations

5

How do life sciences
leaders leverage our
technology
VIDEO, 3 MIN

Why join Voluntis?

Give meaning to your work: Go beyond creating cutting-edge technology. Work to improve a patient’s quality of life and treatment outcomes.

Join a diverse family: You’ll work with the best from a variety of cultural, educational and professional backgrounds. From oncologists to engineers, from the newly-graduated to industry veterans on both sides of the Atlantic, we all enjoy making our different points of view meld.

Play hard: We take the time to enjoy each other. Like playing soccer? Join our weekly team. Black diamond runs your idea of paradise? Pack your boots for our ski weekend. Enjoy music? Bring your sandwich to a lunchtime blind test.

See Open Position

Our culture

Audacity

Here, whether we aim to do something that’s never been done before or just to do something different, nothing is impossible. It’s just a question of how we get there.

Team Spirit

We are able to accomplish great things because we work together, from design brainstorms to daily patient support.

Innovation

Here, whether we aim to do something that’s never been done before or just to do something different, nothing is impossible. It’s just a question of how we get there.

Our people

Lisa Kiblinger

Senior Manager, Medical Affairs Diabetes

Frédéric Tan

Project Manager Diabetes

Mireille Mazloum

Services & Solution Design Manager


Get in touch!

Would like to partner with us? Got a question or a comment?

Contact us

Lorem ipsum title h2

Lorem ipsum title h3

Lorem ipsum title h4

Lorem ipsum title h5
Lorem ipsum title h6

Our solutions combine mobile and web technology, leveraging our proven Theraxium platform, with embedded evidence-based clinical algorithms to adjust treatment dosage

  • Our solutions combine mobile and web technology,
  • leveraging our proven Theraxium platform,
  • with embedded evidence-based clinical algorithms to adjust treatment dosage
€m20192020
Sales invoicing2.710.2
Revenues3.74.4
Adjusted EBITDA(13.4)(3.4)
EBITDA(12.5)(9.1)
Operating income(14.8)(11.1)
Free cash flow(14.3)(2.1)

Oncology

Oncology

Oncology

Press contact

News

Finance 22 June 2020

Application de droits de vote double et impact sur la répartition des droits de vote

Institutional 30 March 2021

2020 annual results in line with the roadmap, demonstrating the success the new strategy, and confirmed confidence in the plan

Institutional 3 September 2020

Appointement of Guillaume Floch as Chief Financial Officer of Voluntis

H1 2021 FINANCIAL REPORT (In French)

October 2021

Complément de la note d’information en réponse à l’Offre Publique d’Achat Simplifiée

September 2021

Complément de l’Offre Publique d’Achat Simplifiée Définitive

September 2021

Note d’information établie par Voluntis en réponse à l’Offre Publique d’Achat Simplifiée

September 2021

Offre Publique D’Achat Simplifiée définitive portant sur les actions de la société Voluntis

September 2021

Lettre aux Actionnaires

September 2021

Communiqué relatif à l’Offre Publique d’Achat Simplifiée visant les actions de la société Voluntis

September 2021

Communiqué de mise à disposition de la note d’information de la société AptarGroup Holding SAS

September 2021

H1 2021 Financial Report (in French)

September 2021

Projet d’offre publique d’achat simplifiée

September 2021

Communiqué du 10 septembre 2021 relatif à la mise à disposition de la note établie par la société Voluntis en réponse au projet d’offre publique d’achat simplifiée

September 2021

Projet de note d’information établie par la société Voluntis en réponse au projet d’offre publique d’achat simplifiée

September 2021

Communiqué du 10 septembre 2021 relatif au dépôt du projet d’offre publique d’achat simplifiée

September 2021

Nombre total d’actions et de droits de vote – 2 septembre 2021

September 2021

Investors Presentation

May 2021

2020 Financial Report (in French)

March 2021

Investors Presentation

March 2021

Information Document (in French)

February 2021

Title – vol events

Label

Lorem ipsum

{text} box
  • titre text

Engineering

With over 40 solutions built and a versatile and modular platform for DTx, the Voluntis team has developed a unique expertise in developing software medical devices. 

agile team co-developing digital therapeutics

Solutions Design

We create digital therapeutics in line with the IEC 62366 for usability and human factors engineering of medical devices.